In gram-negative sepsis, the activation of polymorphonuclear leukocytes (PMN) by lipopolysaccharide (LPS) and the resulting production of superoxide and other oxygen radicals may be an important cause of tissue damage. A suppression of the PMN response to LPS stimulation would be therapeutically beneficial. The aim of this study was to determine whether different polyclonal immunoglobulins (Igs; 5S-Ig, 7S-Ig, and 19S-Ig) influence the PMN response to LPS of Salmonella enteritidis in vitro. The respiratory burst activity of PMN was measured with luminol-enhanced chemiluminescence. After addition of a 5S-Ig solution containing F(ab')2 fragments of IgG and a 19S-Ig solution containing 12% polyclonal IgM, luminol-enhanced chemiluminescence was reduced by 27% (P < 0.05) and 46% (P < 0.005), respectively. However, after addition of a 7S-Ig solution containing polyclonal IgG, luminol-enhanced chemiluminescence was increased fourfold (P < 0.05). The results suggest that the influence of polyclonal Igs on PMN response to LPS stimulation is dependent on the Ig class, F(ab')2 fragments of IgG and IgM leading to LPS neutralization and IgG leading to the production of potentially toxic oxygen radicals.
The treatment of gram-negative sepsis with polyclonal immunoglobulins (Igs) is still the subject of controversy because of inconsistent data from clinical studies (29, 36) . Even with broad-spectrum antibiotics and optimal supportive care, gramnegative sepsis remains a major clinical problem, especially in immunocompromised patients (10, 11, 37, 38) . The tissue damage and the shock syndrome in gram-negative sepsis are due to a cascade of events, in which endotoxin or lipopolysaccharide (LPS), macrophages, polymorphonuclear leukocytes (PMN), and different mediators play a central part (25, 26, 35) . LPS is a component of the outer membrane of gram-negative bacteria and is composed of several variable polysaccharide side chains (O antigen), a central oligosaccharide (core), and the biologically active lipid A (31) .
LPS can directly activate macrophages and PMN or prime both for subsequent activation (41, 44) . Macrophages respond primarily to the LPS stimulus with synthesis of tumor necrosis factor (TNF), interleukin 1, and platelet-activating factor. TNF is responsible for the shock syndrome in gram-negative sepsis (6, 7) . After priming with LPS, macrophages can respond with production of leukotrienes and prostaglandins. PMN respond to LPS with a respiratory burst (20) . During the respiratory burst of PMN, superoxide and other oxygen radicals (hydrogen peroxide, hydroxyl radical, singlet oxygen, and hypochlorous acid) are produced (2) (3) (4) . Superoxide and the other oxygen radicals are responsible for tissue damage in gram-negative sepsis (5, 9, 32, 39) . The oxidizing products of the respiratory burst can be reliably measured with luminol-enhanced chemiluminescence, the oxidation of the chemiluminescent luminol being accompanied by a striking emission of light (1, 21, 27) .
The aim of this study was to investigate in vitro with luminol-enhanced chemiluminescence the influence of differ- (Dulbecco, calcium and magnesium free). The viability of PMN was 95% ± 5%. Incubations. With sterile pipettes, the following substances were added to polystyrene cuvettes and incubated at 37°C in a shaking water-bath: (i) 100 ,ul of PMN cell suspension at 1.25 x 106 cells per ml, (ii) 100 ,ul of luminol (10-5 M), (iii) 50 ,ul of heparinized donor plasma, with PBS as a control, and (iv) 50 ,ul of Ig solution (5S-Ig, 7S-Ig, or 19S-Ig), with human serum albumin as a control. Cells were incubated for 60 min at 37°C to eliminate stimulation through the isolation procedure. In preliminary experiments, it had been verified that neither human serum albumin nor Igs had a stimulatory effect on PMN in the absence of LPS. Therefore, human serum albumin and Igs were added prior to the preincubation. After 60 min of preincubation, the stimulus was added at time zero. The stimulus consisted of 100 ,ul of a solution of S. enteritidis LPS or PMA and PBS as positive and negative controls, respectively. The readings were started immediately after addition of the stimulus and registered every 5 min for 60 min.
MATERLALS AND METHODS

Reagents
Respiratory burst activity. At the times indicated, chemiluminescence was measured in a Lumac-Counter luminometer (Lumac Systems, Basel, Switzerland). The chemiluminescence was recorded in relative light units.
Statistics. Data are expressed as means ± standard errors of the mean for duplicate determinations of three similar experiments. The significance of differences was examined by use of an unpaired Student's t test; P < 0.05 was considered significant.
RESULTS
Stimulation of PMN with PMA. The time course of chemiluminescence in PMN after addition of PMA (10 ,ug/ml), PBS, and LPS (2.5 iig/ml) is depicted in Fig. 1 (2.5 ,ug/ml), chemiluminescence increased rapidly to a peak after 15 min and declined progressively thereafter.
Stimulation of PMN with LPS. The dose-response curve for the stimulation of PMN with S. enteritidis LPS is shown in Fig.  2 . The optimal luminol concentration, i0-5 M, had been determined in preliminary studies. A measurable stimulation of the PMN, as detected with the chemiluminescence assay, was seen with LPS concentrations ranging from 2.5 ,ig/ml to 2.5 ng/ml. The effect was dose dependent. Maximal stimulation was obtained 15 min after addition of LPS at 2.5 ,ug/ml. As stated above, chemiluminescence declined over the following 45 min. When donor plasma was replaced by human serum albumin and when donor plasma was heated for 30 min at 56°C, no stimulation of PMN with LPS was registered (data not shown). This indicates that the activation of PMN in the presence of LPS is complement dependent.
Effect of 5S-Ig. 5S-Igs are G class Igs in which the Fc region is removed by pepsin treatment. Hence, the activation of the complement system and the activation of PMN through the Fc receptor is suppressed, while the antigen binding remains unchanged. The treatment of PMN with a 5S-Ig solution at a concentration of 6.25 mg/ml prior to stimulation with LPS at 2.5 jig/ml resulted in a 27% decrease in chemiluminescence (P < 0.05) (Fig. 3) . The kinetics are shown in Fig. 4A . The steep rise in chemiluminescence obtained with LPS at 2.5 ,ug/ml was suppressed after addition of 5S-Igs. With lower concentrations of LPS (data not shown) or 5S-Ig concentrations of 625 or 62. 5 ,ug/ml, the decrease in chemiluminescence was not significant (Fig. 4A) . It had been determined in preliminary studies that the 5S-Igs used had no effect on PMN in the absence of LPS.
Effect of 7S-Ig. 7S-Igs are G class Igs in which the Fc and Fab regions are unaltered. The treatment of PMN with a 7S-Ig solution at a concentration of 6.25 mg/ml prior to stimulation with LPS at 2.5 ,ug/ml resulted in a significant (ca. fourfold) increase in chemiluminescence (P < 0.05) (Fig. 3) . The kinetics are shown in Fig. 4B (Fig. 4B) , the increase was not significant. (Fig. 3) . The kinetics are shown in Fig. 4C . The effect was seen over the registered period. Nevertheless, the chemiluminescence increased slowly during the second half of the experiment. Again, the effect was not significant with lower concentrations of LPS (data not shown) or 19S-Igs (Fig. 4C) .
DISCUSSION
Considering the LPS concentrations in our in vitro model, some restrictions have to be observed before extrapolating the results to clinical practice. The LPS concentrations used, 2.5 ,ug/ml to 2.5 ng/ml, were higher than found in bacteremia with the Limulus amebocyte lysate assay. However, concentrations were similar to those employed by other investigators for nonlethal bolus injections or continuous infusions of LPS in animals (9, 24, 34) . In our study, the neutrophils were also stimulated with lower LPS concentrations, 250 and 25 ng/ml, but to a highly variable extent. The concentrations of Igs used in the study were comparable to those used under clinical conditions. The sensitivity of our chemiluminescence assay and the kinetics obtained with PMA and LPS were comparable to those found in the literature (15, 28, 43) . Complementdependent stimulation of PMN by LPS was indicated by the fact that with human serum albumin or with heated donor plasma replacing donor plasma in the assay, no relevant increase in chemiluminescence was recorded. This is consistent with the theory that smooth-form LPS, like the S. enteritidis LPS chosen, requires the activation of the complement system via the alternative pathway before stimulating PMN (14, 45) .
Treatment of the PMN with 5S-Igs before stimulation with LPS resulted in a 27% reduction in chemiluminescence. 5S-Igs are Ig molecules split by the proteolytic enzyme pepsin so as to remove the Fc portion and leave the two antigen-binding arms (Fab) connected, the bivalent portion being called F(ab')2. Therefore, complement and PMN should not be activated via the Fc portion. We conclude that the reduction in neutrophil oxygen burst by 5S-Igs may due to a neutralization of the LPS stimulus by the F(ab')2 fragments. The mechanisms of neutral- (37) . That a reduction in chemiluminescence was recorded in the presence of 76% IgG may be explained by the fact that the neutralizing effect of IgM is more effective than or even prevents the stimulating effect of IgG.
Taken together, our data suggest that the composition of the polyclonal Igs [F(ab')2 fragments, unaltered IgG, or IgM] largely influences their effect on the PMN response to LPS stimulation. Since the preparations used in this study have not been characterized with respect to the binding capacity for S. enteritidis LPS, it cannot be excluded that differences between the various preparations in the ability to bind LPS affected the PMN response. However, major differences seem unlikely in view of the very similar binding capacity of polyclonal IgG for numerous antigens tested by the manufacturers. Furthermore, the disparity between preparations obtained from the plasma of more than 1,000 donors should be minimal. Thus, it appears that the variable composition of the polyclonal Igs may be one reason for the equivocal results of clinical studies, i.e., with antibodies to J5 (12, 47) , and should be respected in further trials.
